SCHEMBL24998

SCHEMBL24998

CCCCc1[c]cccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
DRD3 P35462 2/20 0.34
DRD2 P14416 1/20 0.34
CFTR P13569 4/20 0.33
HPGD P15428 1/20 0.33
CTRC Q99895 1/20 0.33
KCNH2 Q12809 1/20 0.32
SIGMAR1 Q99720 2/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD11B1 P28845 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19405573 0.94 KCNH2 (0.39) KDM4ELMNADRD3DRD2CFTR
SCHEMBL25065 0.93 KCNH2 (0.42) KDM4ELMNAKCNH2MEN1KMT2A
SCHEMBL6558277 0.93 KCNH2 (0.42) KDM4ELMNAKCNH2MEN1KMT2A
SCHEMBL10661017 0.93 KCNH2 (0.42) KDM4ELMNAKCNH2MEN1KMT2A
SCHEMBL9322491 0.88 LMNA (0.31) KDM4ELMNA
SCHEMBL19405458 0.80 SLC6A2 (0.35) KDM4E
SCHEMBL455750 0.79
SCHEMBL677297 0.78 LIPG (0.39) CTRCKCNH2
SCHEMBL819968 0.78 SKP2 (0.35) HPGDKCNH2HTTHSD11B1
SCHEMBL815623 0.77 GABRA1 (0.34) DRD3DRD2CTRCKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107004906-B Magnesium-containing electrolyte 富士胶片和光纯药株式会社 2020-04-21 CN disclosed
US-10367231-B2 Magnesium-containing electrolytic solution FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-07-30 US disclosed
EP-3226340-B1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2018-11-07 EP disclosed
US-20170331154-A1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2017-11-16 US disclosed
EP-3226340-A1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION Wako Pure Chemical Industries, Ltd. (JP) 2017-10-04 EP disclosed
EP-2588480-A2 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF& xA; SANOFI (FR) 2013-05-08 EP disclosed
WO-2011161537-A2 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-29 WO disclosed
US-4105685-A B-HALOGENO-ETHYL SILANES CIBA-GEIGY CORPORATION (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10367231-B2 Magnesium-containing electrolytic solution CA1, CA3, CA2 KDM4E 3595/4885LMNA 2142/4885DRD3 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.